Small molecule activators of protein phosphatase 2A (PP2A), hereafter SMAPs, have attracted substantial interest for their potential to inhibit cancer cell proliferation by targeting PR65, the scaffold subunit of the PP2A heterotrimer. The gene discussed is PTPA; the disease is cancer.